Our news

18.04.2023

NeoPhore signs research collaboration with The Institute of Cancer Research, London

London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic c…

19.01.2023

NeoPhore completes extension to Series B financing to further advance discovery pipeline

Scientific milestones achieved significantly ahead of schedule Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen i…

28.07.2022

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center

Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a t…

18.02.2022

St George’s expands successful collaboration in pursuit of new, first-in-class cancer therapies

St George’s, University of London and NeoPhore today announce the expansion of their research partnership after a successful collaboration i…

Other news

06.08.2019

BioCentury's Emerging Company Profile

CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…

08.02.2018

NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology

Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…